Streetbeat News

Products Services

BABA

NXPL

NextPlat Corp has received initial approvals to launch an OPKO Health-branded storefront on Alibaba's Tmall Global platform in China, aiming to sell up to 40 health and wellness products. This move, part of an exclusive joint e-commerce development agreement with OPKO Health Europe, a subsidiary of OPKO Health, Inc., marks a strategic milestone for NextPlat in tapping into the global health and wellness market. The company plans to expand its offerings and is awaiting final Chinese regulatory approval to include veterinary and animal health products. The initiative is expected to create a new international e-commerce revenue stream for NextPlat and is supported by local online specialists and Tmall Global-preferred merchant partners.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:13 pm

CLDX

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its Phase 2 clinical trial results of barzolvolimab for chronic spontaneous urticaria (CSU) will be presented at the AAAAI 2024. The study, involving 208 patients, evaluates the efficacy and safety of barzolvolimab in CSU patients unresponsive to antihistamines. Results show significant decrease in disease activity and good tolerance. The presentation is scheduled for February 24, 2024, with a webcast on February 25.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:12 pm

MTEK

Maris-Tech Ltd. has received an order worth approximately $190,000 from a returning customer for a miniature low-power solution aimed at improving gun sight capabilities in tactical applications.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:12 pm

JSPR

Jasper Therapeutics announced its participation in the American Academy of Allergy, Asthma, and Immunology Annual Meeting with presentations on preclinical data for Briquilimab, an Anti-CD117 antibody. The data shows Briquilimab's potential in preventing systemic anaphylaxis, allergic asthma, and anaphylactoid drug reactions in mice models. The presentations are scheduled for February 23-25, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:11 pm

RANI

Rani Therapeutics announced positive Phase 1 study results for RT-111, an oral anti-Interleukin 12/23 antibody, showing high bioavailability and tolerability with no serious adverse events. Celltrion has the right of first negotiation for worldwide rights to RT-111 post-trial. This marks Rani's third successful Phase 1 trial using RaniPill technology. A conference call is scheduled for today.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:09 pm

JNJ

Johnson & Johnson announced positive topline results for Nipocalimab in Phase 3 and Phase 2 studies for treating generalized Myasthenia Gravis (gMG) and Sjögren's Disease (SjD), respectively. Nipocalimab showed clinical efficacy in gMG, addressing a significant unmet need for effective and safe therapies. It is also the first anti-FcRn to demonstrate efficacy in SjD, a prevalent autoantibody disease lacking advanced treatments. Over the past year, Nipocalimab has shown effectiveness in four different autoantibody-driven diseases.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:07 pm

NKLA

Nikola Corporation has inaugurated its HYLA hydrogen fueling station in Southern California, marking a significant step in the company's efforts to expand its hydrogen fuel infrastructure.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:06 pm

OCUP

Ocuphire Pharma, Inc. (NASDAQ:OCUP) presented clinical data from its ZETA-1 trial on APX3330 for diabetic retinopathy at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference. The trial showed a reduction in disease worsening with 24 weeks of APX3330 treatment. Ocuphire plans to finalize the Phase 3 program protocol with the FDA, highlighting APX3330's potential as an oral treatment option for non-proliferative diabetic retinopathy.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:06 pm

CZOO

MBLY

PDD

TSLA

WW

The article highlights the top 5 consumer discretionary stocks considered oversold based on their Relative Strength Index (RSI) values, indicating potential buying opportunities. These include Mobileye Global Inc. (MBLY), Cazoo Group Ltd (CZOO), WW International, Inc. (WW), Tesla, Inc. (TSLA), and PDD Holdings Inc. (PDD), with recent financial results and stock performance discussed for each.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:05 pm

OII

Oceaneering International, Inc. (NYSE:OII) has secured multiple contracts in Q4 2023 for its Manufactured Products segment, totaling an anticipated revenue of approximately $200 million. These contracts, primarily with international oil and gas operators and marine construction companies, include significant projects in the Gulf of Mexico and the Black Sea, involving the supply of electro-hydraulic, steel tube umbilicals and supporting hardware. Production for these projects is scheduled across facilities in Panama City, Houston, and Rosyth, with final deliveries expected between Q3 2025 and Q3 2026. CEO Rod Larson highlighted these awards as a testament to Oceaneering's role in supporting global offshore energy production and customer operations.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:05 pm